LONDON, November 19, 2015 /PRNewswire/ --
- The average cost of care in Belgian patients using real world evidence was shown
to be EUR31,262 for rifaximin-alpha 550mg plus lactulose versus EUR44,190 for
lactulose alone 
- In a Dutch societal framework rifaximin-alpha 550mg has demonstrated an incremental
cost-effectiveness ratio of EUR31,897 
Norgine B.V. has presented new analyses demonstrating the cost effectiveness of XIFAXAN(R) / TARGAXAN(R) 550 (rifaximin-alpha 550mg) treatment in Belgian and Dutch cirrhotic patients with recurrent hepatic encephalopathy with standard of care (lactulose) versus standard of care alone., These data were presented at the ISPOR Annual Congress 2015, Milan, Italy.
(Logo: http://photos.prnewswire.com/prnh/20130829/633895-a )
The Belgian analyses demonstrate that over a five-year time horizon, treatment with rifaximin-alpha 550mg plus lactulose was both less costly and more effective than with lactulose alone. The analysis was derived from estimates of cost and quality adjusted life year (QALY) measures, which were based on key parameters, including length of hospital stay and number of hospital admissions.
In Dutch patients, the data show use of rifaximin-alpha 550mg plus lactulose represented good use of economic resource and was cost-effective compared with lactulose alone. Outcome metrics were incremental cost effectiveness ratios (ICERs) derived from QALY estimates and estimates of impact of work productivity loss upon patient/carer using a friction cost method reflecting patient and societal considerations in the model.
Both studies showed positive data for rifaximin-alpha 550mg, demonstrating a cost saving in Belgium of EUR12,927 per person over a 5 year time horizon. In the Netherlands, a cost effective base-case ICER of EUR31,897 over a lifetime horizon was demonstrated., 
Peter Martin, Chief Operating Officer at Norgine said "These new analyses are significant because they further demonstrate the value of XIFAXAN(R) / TARGAXAN(R) 550 as an effective treatment to manage hepatic encephalopathy, a debilitating condition that currently has no cure apart from liver transplantation."
See full release on http://www.norgine.com
1. Evaluation of the cost effectiveness of rifaximin-alpha 550mg in the reduction of recurrence of overt hepatic encephalopathy in Belgium. ISPOR Annual Congress 2015, Abstract PGI25.
2. Evaluation of the cost effectiveness and societal impact of rifaximin-alpha 550mg in the reduction of recurrence of overt hepatic encephalopathy in the Netherlands. ISPOR Annual Congress 2015, Abstract PGI38.
Isabelle Jouin, T: +44-(0)1895-453643
Charlotte Andrews, T: +44-(0)1895-453607
Follow us @norgine